nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Medical Admissions Among Adolescents With Eating Disorders During the COVID-19 Pandemic
July 27, 2021   

The COVID-19 pandemic has reportedly been associated with worsening symptoms of eating disorders in both adults and adolescents. In a recent study, a chart review of patients ages 10-23 admitted to a children’s hospital for restrictive eating disorders from March 2017 to March 2021 was conducted. Eating disorder-related medical admissions at the hospital increased significantly during the...
 Continue reading (Members only)
Slow-Release Oral Morphine May Help Patients With OUD
July 23, 2021   

Opioid use disorder (OUD), including use of both heroin and prescription opioids, is a problem of great concern across the globe. Treatments with the greatest promise include medication assisted therapies whereby an individual is treated with an opioid agonist (such as methadone), partial antagonist (such as buprenorphine), or antagonist (such as naltrexone). Additionally...
 Continue reading (Members only)
Shared Cultural Values Influence Mental Health Help-Seeking Behaviors
July 16, 2021   

Although Asian and Latinx young adults may be at higher risk of mental health issues, alarming data suggests that such individuals are less likely to see and receive mental health care services. There are several suggestions to explain this discrepancy. “Familism”, which is a duty to one’s family, may have the pros of supportive family ties but may also have...
 Continue reading (Members only)
Total Cost of Schizophrenia in the US is Estimated at $281.6 Billion in 2020
July 14, 2021   

The Schizophrenia & Psychosis Action Alliance released "Societal Costs of Schizophrenia and Related Disorders," a report that identifies the direct and indirect costs of caring for the estimated 2.65 million people in the U.S. living with schizophrenia. The research revealed that schizophrenia cost the US an estimated $281.6 billion in 2020...
 Continue reading
Anti-Inflammatory, Antidepressant, And Neuroprotective Effects Of Fish Oil Revealed
July 13, 2021   

The fish-derived omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid have antidepressant, anti-inflammatory, and neuroprotective properties; however, the exact molecular mechanisms are unknown. A recent study investigated these mechanisms in vitro using the immortalized human hippocampal...
 Continue reading (Members only)
Factors Associated With Stimulant Treatment Outcomes in ADHD
July 9, 2021   

Stimulant medications are the first-line recommended treatment for attention deficit hyperactivity disorder (ADHD); however, many patients discontinue treatment or switch to nonstimulant ADHD medications. A recent study investigated the genetic, clinical, and sociodemographic factors that influence stimulant treatment initiation, discontinuation, and switch to nonstimulant medications in ADHD. The study included...
 Continue reading
Association of Cannabis Use During Adolescence With Neurodevelopment
July 6, 2021   

The association between cannabis use and adolescent neurodevelopment is not well characterized longitudinally. Data from the IMAGEN study, a community-based cohort study conducted across eight sites in western Europe, was used to examine the association between cerebral cortical thickness and cannabis use in mid to late adolescence. Participants...
 Continue reading (Members only)
Pharmacogenetic-Guided Treatment Shows No Benefit Over Standard Treatment for Adolescents With MDD
July 2, 2021   

The use of pharmacogenetics in clinical practice is growing, due to numerous commercial pharmacogenetics panels now widely available. A recent double-blind, randomized study was conducted to prospectively evaluate the clinical impact of combinatorial pharmacogenetics testing in adolescents with depression. Adolescents...
 Continue reading (Members only)
FDA Grants Accelerated Approval for Alzheimer’s Drug
June 22, 2021   

It has been 2 decades since pre-clinical research on passive immunotherapy for Alzheimer’s disease began and the effort of thousands of researchers seems to finally be paying off. Aducanumab, a passive immunotherapy consisting of anti-amyloid human monoclonal antibodies, has been shown to reduce brain amyloid burden and...
 Continue reading (Members only)
PsychopharmaStahlogy Show: Treatment-Resistant Depression and Suicide Prevention
June 18, 2021   

The PsychopharmaStahlogy Show is a special podcast series released on the NEI Podcast. In the second three part series, Dr. Stephen Stahl addresses treatment-resistant depression and suicide prevention along side experts, Dr. Andrew Cutler, Dr. Roger McIntyre, and Dr. Christine Moutier...
 Continue reading
12345678910...
Top of Page